<DOC>
	<DOCNO>NCT00016016</DOCNO>
	<brief_summary>Phase II trial study effectiveness combine flavopiridol cytarabine mitoxantrone treat patient acute leukemia . Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell .</brief_summary>
	<brief_title>Flavopiridol , Cytarabine , Mitoxantrone Treating Patients With Acute Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine toxicity escalate dos flavopiridol administer timed sequence ara-C mitoxantrone adult refractory relapse acute leukemias high-risk myelodysplasias ( MDS ) . II . To determine flavopiridol administer time sequence ara-C Mitoxantrone induce clinical response adult refractory relapse acute leukemias MDS . III . To determine flavopiridol directly cytotoxic leukemic blast vivo . IV . To determine flavopiridol recruit synchronize residual leukemic blast proliferate vivo . OUTLINE : This dose-escalation study flavopiridol . ( Phase I close accrual effective10/24/2003 ) . Patients receive flavopiridol IV 1 hour day 1-3 cytarabine IV continuously day 6-9 follow mitoxantrone IV 30-150 minute day 9 . Patients achieve partial complete response first course therapy may receive additional course therapy begin 35 Â± 7 day blood count recovery . Cohorts 3-6 patient receive escalate dos flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . ( Phase I close accrual effective 10/24/2003 ) . Once MTD reach , additional patient accrue receive flavopiridol recommend phase II dose .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Established diagnosis poorrisk hematologic malignancy consider eligible Phase I/II study Pathological confirmation diagnosis AML ALL ECOG performance status 0,1,2 Patients must able give informed consent Female patient childbearing age must negative pregnancy test AST ALT = &lt; 2.5 x normal Alkaline phosphatase = &lt; 2.5 x normal Bilirubin = &lt; 1.5 x normal Serum creatinine = &lt; 2.0 mg/dl Left ventricular ejection fraction must &gt; = 45 % MUGA Echocardiogram Acute Myelogenous Leukemia ( AML ) AML arise MDS Secondary AML Relapsed refractory AML , include primary induction failure Acute Lymphoblastic Leukemia ( ALL ) Relapsed refractory ALL , include primary induction failure Patients fail primary induction therapy relapse achieve complete remission ( CR ) eligible undergone 3 prior course induction/reinduction There interval least 4 week previous intensive chemotherapy begin flavopiridol , exception nonaplasia produce treatment ( i.e . hydroxyurea , interferon , imatinib , 6MP , thalidomide ) ; patient recover completely treatmentrelated toxicity ; patient may receive hematopoietic growth factor previously , must growth factor ( include EPO , GCSF , GMCSF , IL3 , IL11 ) least 4 day prior begin flavopiridol Patients undergone stem cell transplantation ( SCT ) , autologous allogeneic , eligible provide &gt; = 4 week stem cell infusion , active GVHD , meet eligibility criterion Hyperleukocytosis &gt; = 50,000 leukemic blasts/mm^3 Active , uncontrolled infection Disseminated intravascular coagulation Active CNS leukemia Concomitant chemotherapy , radiation therapy immunotherapy Intrinsic impair cardiac function ( MI within precede 3 month history severe coronary artery disease , cardiomyopathy , CHF &gt; Class II ) History congestive heart disease , arrhythmia without regard time , severity resolution Women pregnant lactate eligible trial , investigational agent may harmful develop fetus nursing infant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>